df-mp - Global Expertise for Your Innovations and Trademarks
df-mp is a top firm in intellectual property law with an international outlook and a broad scope of specialized expertise. Globally-oriented companies in such practice areas as biotechnology, chemistry,
mechanical and electrical engineering and pharmaceuticals trust the competent advice offered by our highly-rated team.
df-mp - Dual Qualifications in Europe and the U.S.
The patent attorneys of df-mp are specialized in proceedings in Germany and Europe, as well as the U.S. We are thus in the unique position to be able to develop comprehensive
intellectual property protection strategies for you and your company that account for legal requirements in Europe and the U.S.
df-mp - Firm History
df-mp was founded in Munich in 2000 by the partners Dr. H. Ulrich Dörries, David Molnia and Sandra Pohlman.
The firm has been growing steadily as other patent attorneys have joined the firm. In 2007, Dr. Michael Eder has been appointed as a partner at df-mp. Meanwhile, df-mp has become a
leading intellectual property firm in its practice areas. Since the summer of 2007, the office is located at the exclusive "Fünf Höfe" in the heart of Munich.
df-mp - Career Opportunities
df-mp is continuously growing. Here you can find our current job offers.
back to the top
DEUTSCH |
ENGLISH
ContactDisclaimer
df-mp - News
df-mp - IP News
A Blow to Broad Medical Use Claims from Technical Board 3.3.10?
In a recent decision (T 1063/06) Technical Board of Appeal 3.3.10 ruled that a Swiss-type claim relating to the use of a "functionally" defined compound (stimulator)is to be considered as a "reach-through" claim that does not fulfill the requirements of Article 83 EPC (sufficiency of disclosure).read more
The practice of filing European divisional applications will fundamentally change as of 1 April 2010
As of 1 April 2010 the EPO will change its practice in filing divisional applications which will have a major influence on prosecution strategy and management of patent portfolios read more
German Federal Supreme Court Refines Novelty Test in Chemical Cases in Lilly's "Olanzapine" Case
The Federal Supreme Court (FSC) had recently decided to annul the German Federal Patent Court's earlier decision to revoke the German part of Eli Lilly's European patent EP 454 436-B1 to Olanzapine (Zyprexa®) in a hearing held on December 16, 2008. The eagerly awaited written decision is now available read more
Bill for the Modernisation of German Patent Law
On October 15, 2008 a bill was agreed upon by the Federal Government to simplify and modernise patent law in Germany. The new law is yet to be ratified by the German Parliament ("Bundestag"). The aim of the changes to the law is to simplify the filing of patents and trademarks and to shorten court proceedings, particularly in patent nullity proceedings. read more
EPO Enlarged Board of Appeal renders decision in G 2/06 "WARF/Thomson stem cell application"
The Enlarged Board of Appeal (EBoA) of the EPO has made a ruling in an appeal connected to the so-called WARF/Thomson stem cell application. The ruling contains clarifications to questions posed by a Technical Board of Appeal dealing with the patentability of the WARF application. read more
Contact
df-mp
Fünf Höfe
Theatinerstraße 16
80333 Munich
Phone: + 49 89 210 296 0
Fax:+ 49 89 210 296 33
info@df-mp.com
